Description
ADCC-enhanced lifastuzumab vedotin is a non-fucosylated anti-SLC34A2 therapeutic biobetter antibody.
Antibody Indication
Ovarian cancers
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced SLC34A2 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
SLC34A2
Full Name
Solute Carrier Family 34 Member 2
Background
The protein encoded by this gene is a pH-sensitive sodium-dependent phosphate transporter. Phosphate uptake is increased at lower pH. Defects in this gene are a cause of pulmonary alveolar microlithiasis. Three transcript variants encoding two different isoforms have been found for this gene. [provided by RefSeq, May 2010]
Alternative Names
SLC34A2; solute carrier family 34 (type II sodium/phosphate contransporter), member 2; NPTIIb; NAPI-3B; NAPI-IIb; sodium-dependent phosphate transport protein 2B; sodium/phosphate cotransporter 2B
Gene ID
10568
UniProt ID
O95436
Cellular Localization
Membrane
Involvement in Disease
Diseases associated with SLC34A2 include Pulmonary Alveolar Microlithiasis and Testicular Microlithiasis.
Related Pathways
Its related pathways are Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds and Mineral absorption.
Function
It may be involved in the transport of phosphate into cells via Na(+) cotransport. It may be the main phosphate transporter in the brush border membrane of the intestine. May be involved in the synthesis of surface active substances in the alveoli.
Post-translational modifications
1.Glycosylation at Asn295, Asn308, Asn313, Asn321, and Asn340 2.Modification sites at PhosphoSitePlus
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG
Antibody Clone
lifastuzumab vedotin
Description
ADCC-enhanced lifastuzumab vedotin is a non-fucosylated anti-SLC34A2 therapeutic biobetter antibody.
Antibody Indication
Ovarian cancers
